ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,356.83
-0.16%
Dow Jones
39,671.04
-0.51%
Gold vs US Dollar
2,362.89
-0.80%
Brent Oil
81.60
0.09%
Bitcoin
69,735.42
0.92%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. HUTCHMED China Limited (HCM)

  7. HUTCHMED China Limited (HCM) News

HUTCHMED China (HCM)

HUTCHMED China Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HCM
DateTimeSourceHeadlineSymbolCompany
17/05/202415:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
17/05/202415:00GlobeNewswire Inc.HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committeesNASDAQ:HCMHUTCHMED China Limited
17/05/202401:00GlobeNewswire Inc.HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 CongressNASDAQ:HCMHUTCHMED China Limited
14/05/202401:00GlobeNewswire Inc.HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with HengruiNASDAQ:HCMHUTCHMED China Limited
14/05/202401:00GlobeNewswire Inc.HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in ChinaNASDAQ:HCMHUTCHMED China Limited
08/05/202409:30GlobeNewswire Inc.HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNASDAQ:HCMHUTCHMED China Limited
26/04/202413:30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
05/04/202409:30GlobeNewswire Inc.HUTCHMED Highlights Data to be Presented at AACR Congress 2024NASDAQ:HCMHUTCHMED China Limited
02/04/202405:30GlobeNewswire Inc.HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
28/03/202400:00GlobeNewswire Inc.HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCNASDAQ:HCMHUTCHMED China Limited
22/03/202400:00GlobeNewswire Inc.HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaNASDAQ:HCMHUTCHMED China Limited
05/03/202411:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202411:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202411:40Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:HCMHUTCHMED China Limited
28/02/202411:30GlobeNewswire Inc.HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
07/02/202411:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
07/02/202400:00GlobeNewswire Inc.HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionNASDAQ:HCMHUTCHMED China Limited
02/02/202411:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
02/02/202408:30GlobeNewswire Inc.HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipNASDAQ:HCMHUTCHMED China Limited
01/02/202411:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
01/02/202408:30GlobeNewswire Inc.HUTCHMED to Announce 2023 Final ResultsNASDAQ:HCMHUTCHMED China Limited
30/01/202411:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
30/01/202404:53GlobeNewswire Inc.HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
11/01/202411:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
11/01/202400:00GlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
29/12/202311:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
21/12/202311:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
13/12/202311:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
13/12/202304:30GlobeNewswire Inc.HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsNASDAQ:HCMHUTCHMED China Limited
13/12/202300:00GlobeNewswire Inc.HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaNASDAQ:HCMHUTCHMED China Limited
 Showing the most relevant articles for your search:NASDAQ:HCM

Your Recent History

BIT
NSCIT2581212
International Bank for R...
USOTC
BGNX
BIO Genex Laboratories (CE)
USOTC
BLIDF
Boliden AB (PK)
LSE
FADL
Fadel Partners
DBI
I9NZ
IN XTK 2 TMASE33 CB EO
NYSE
SB-B
ASX
NTMN
Northern Manganese
BOV
KLBN3Q
KLABIN ON
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved